Recent case reports have recognized chronic thromboembolic pulmonary hypertension (CETPH) as an important complication of slow-flow vascular malformations.1- 7 This month's issue of the Archives features the first case-control study exploring the prevalence of pulmonary hypertension (PH) in patients with extensive slow-flow vascular malformations.
In the presented case-control study, Rodríguez-Mañero et al8 evaluated 32 asymptomatic patients with extensive slow-flow vascular malformations (involving at least 15% of the body surface area) for evidence of PH using transthoracic echocardiography. Their most important finding is that in 22% of these patients the estimated pulmonary arterial systolic pressure (PASP) was 50 mm Hg or higher. Although the authors did not perform catheterization of the right side of the heart to confirm or rule out the presence of PH in their patients, this implies that in a considerable number of patients the diagnosis of PH is very likely.9 Moreover, another 50% of the evaluated patients had estimated PASP values of 37 to 50 mm Hg, which suggests that a diagnosis of PH is very possible. Thus, following international guidelines for diagnosis and treatment of PH in as many as 72% of the patients evaluated, further diagnostic workup is warranted.9,10
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Clinical classification of pulmonary hypertension. (Simonneau et al11). ALK1 indicates activin receptor-like kinase type 1; BMPR2, bone morphogenetic protein receptor type 2; HIV, human immunodeficiency virus; and PAH, pulmonary arterial hypertension.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.